MetaStat, Inc. (MTST) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
MetaStat, Inc. (MTST) trades at $0.001 with AI Score 57/100 (Grade B). MetaStat, Inc. is a precision medicine company dedicated to discovering and developing therapeutic and diagnostic solutions for cancer patients. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for MTST: MTST does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MTST against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
MTST: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
MetaStat, Inc. (MTST) Healthcare & Pipeline Overview
MetaStat, Inc. is a Boston-based precision medicine company specializing in cancer therapeutics and diagnostics, targeting the pro-metastatic MENA pathway. It develops novel drug candidates and companion diagnostic tests to address tumor resistance and metastasis, positioning itself in the evolving personalized oncology market.
What Is the Investment Thesis for MTST?
MetaStat, Inc. is positioned within the growing precision oncology market, focusing on the critical MENA pathway for both therapeutic and diagnostic development. The company's dual approach, developing novel drug candidates and companion diagnostics, addresses the significant unmet need in predicting and treating cancer metastasis and tumor resistance. With a gross margin of 100.0%, the company demonstrates strong potential for profitability on its products, once commercialized, despite a current profit margin of -13652.5% reflecting its development stage. The demand for personalized medicine and advanced diagnostic tools, particularly those that can predict drug responses and metastasis risk, represents a substantial market opportunity. The company's proprietary molecular assays targeting the MENA pathway could offer a competitive advantage in a highly specialized segment of cancer treatment. However, as an OTC Other listed company with a market capitalization of $0.00B and a high beta of 9.69, MTST carries significant risk related to liquidity, regulatory hurdles, and the inherent challenges of bringing novel biotechnologies to market. Future growth hinges on successful clinical trials, regulatory approvals, and effective commercialization strategies.
Based on FMP financials and quantitative analysis
MTST Key Highlights
MetaStat, Inc. maintains a gross margin of 100.0%, indicating that its current revenue-generating activities, if any, or its cost structure for product development, are highly efficient in terms of direct production costs.
- The company operates with a profit margin of -13652.5%, reflecting its early-stage development phase where significant investments in research and development typically precede substantial revenue generation.
- MetaStat, Inc. has a market capitalization of $0.00 billion, which signifies its status as a micro-cap or pre-revenue company with a very small public valuation.
- The company's Beta is recorded at 9.69, suggesting an extremely high volatility relative to the broader market, which is characteristic of highly speculative, early-stage biotechnology firms.
- MetaStat, Inc. operates with a lean team of 6 employees, indicating a focused and potentially agile organizational structure for its specialized research and development efforts.
Who Are MTST's Competitors?
MTST is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.21% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MTST's Key Strengths?
Specialized focus on the critical MENA pathway for both cancer therapeutics and diagnostics.
- Development of proprietary molecular assays, including tissue-based and liquid biopsy diagnostics.
- Positioned within the high-growth precision medicine and personalized oncology market segments.
- High gross margin of 100.0% suggests efficient cost management for product development activities.
What Are MTST's Weaknesses?
Extremely negative profit margin (-13652.5%) indicates significant ongoing R&D expenses without substantial revenue.
- Very small employee base of 6, potentially limiting scope and speed of development.
- OTC Other listing with unknown disclosure status, which can impact investor confidence and liquidity.
- Market capitalization of $0.00B reflects a very early stage or pre-revenue company with high investment risk.
What Could Drive MTST Stock Higher?
MTST catalyst: **Positive Clinical Trial Results**: Favorable outcomes from ongoing or future clinical trials for MetaStat's therapeutic candidates or diagnostic assays targeting the MENA pathway could significantly validate its technology and attract investor interest.
- **Regulatory Approvals**: Securing FDA or other international regulatory approvals for any of its diagnostic products, such as the MENA diagnostic assay or the liquid blood-based biopsy, would be a critical milestone for commercialization.
- **Strategic Partnerships**: Formation of collaborations or licensing agreements with larger pharmaceutical or diagnostic companies could provide crucial funding, expertise, and market access for MetaStat's pipeline.
- **Advancements in Precision Medicine**: Continued industry-wide growth and acceptance of personalized medicine approaches in oncology could create a more favorable market environment for MetaStat's targeted diagnostics and therapeutics.
What Are the Key Risks for MTST?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- **Clinical Trial Failures**: The inherent risk of biotechnology development means that therapeutic candidates or diagnostic assays may fail to demonstrate efficacy or safety in clinical trials, leading to significant setbacks.
- **Regulatory Setbacks**: Delays or outright rejections in obtaining regulatory approvals from health authorities could significantly impede commercialization efforts and deplete financial resources.
- **Funding Challenges**: As an early-stage company with a negative profit margin and $0.00B market cap, MetaStat faces ongoing challenges in securing sufficient capital to fund extensive research, development, and potential commercialization activities.
- **Intense Competition**: The oncology and diagnostics markets are highly competitive, with numerous well-funded companies developing similar or superior technologies, potentially limiting MetaStat's market penetration.
- **OTC Market Liquidity and Transparency**: The 'OTC Other' listing and 'Unknown' disclosure status present ongoing risks related to low trading volume, wide bid-ask spreads, and limited public information, making the stock highly illiquid and speculative.
What Are the Growth Opportunities for MTST?
- **Advancement of MENA Pathway Therapeutics**: MetaStat, Inc. is developing novel drug candidates that target the critical metastatic MENA pathway in solid tumors. This pathway is responsible for driving tumor resistance and the spread of aggressive cancer, representing a significant unmet medical need. The global oncology drug market is projected to reach over $300 billion by the early 2030s, with a substantial portion dedicated to targeted therapies. Successful progression through clinical trials and eventual regulatory approval of a therapeutic agent could unlock access to this multi-billion-dollar market, offering a long-term revenue stream and establishing MetaStat as a key player in precision oncology.
- **Commercialization of MENA Diagnostic Assay**: The MENA diagnostic assay, a tissue-based quantitative immunofluorescence test, measures the expression of the pro-metastatic MENA protein splice-variant. This diagnostic tool has the potential to provide crucial information for cancer prognosis and treatment selection. The global cancer diagnostics market is estimated to grow to over $250 billion by 2030, driven by increasing demand for early and accurate detection. Successfully bringing this assay to market, obtaining regulatory clearances, and securing adoption by oncology practices and pathology labs could establish a near-to-mid-term revenue stream for MetaStat.
- **Development of Companion Diagnostics**: MetaStat's companion diagnostics aim to predict responses to RTK inhibitor and anti-microtubule drugs. The market for companion diagnostics is expanding rapidly, driven by the shift towards personalized medicine and the increasing complexity of targeted therapies. This market is expected to exceed $10 billion by 2028. By developing diagnostics that enhance the efficacy and safety of existing or pipeline oncology drugs, MetaStat can form strategic partnerships with pharmaceutical companies, potentially generating licensing fees or co-development revenues and integrating its technology directly into established treatment protocols.
- **Innovation in Liquid Blood-Based Biopsy**: The company is developing a liquid blood-based biopsy to enhance cancer diagnosis and optimize patient care. Liquid biopsies represent a less invasive and potentially more convenient alternative to traditional tissue biopsies, with the global market projected to reach over $20 billion by 2030. This technology offers significant advantages in monitoring disease progression, detecting recurrence, and guiding treatment decisions. Successful development and commercialization of this platform could position MetaStat at the forefront of non-invasive cancer diagnostics, appealing to a broad range of healthcare providers and patients seeking advanced, less burdensome diagnostic options.
- **Expansion with MetaSite Breast Assay and Prognostic Diagnostic**: The MetaSite Breast assay, an immunohistochemistry test, measures micro-anatomical intravasation sites, while a prognostic diagnostic predicts the risk of cancer metastasis. These tools address critical needs in breast cancer management and general cancer prognosis. The market for breast cancer diagnostics alone is substantial, with significant demand for tools that can accurately predict metastasis. By providing more precise prognostic information, MetaStat can improve clinical decision-making, potentially leading to better patient outcomes and securing a valuable niche within the oncology diagnostic market in the mid-to-long term.
What Threats Does MTST Face?
- High regulatory hurdles and lengthy approval processes inherent in the biotechnology and pharmaceutical industries.
- Intense competition from well-capitalized pharmaceutical and biotechnology companies.
- Significant capital requirements for clinical trials and commercialization, potentially leading to dilution or funding challenges.
- Liquidity and transparency issues associated with its OTC Other market listing, impacting investor interest and valuation.
What Are MTST's Competitive Advantages?
- Proprietary focus on the MENA pathway, a critical mechanism for tumor resistance and metastasis, offering a specialized niche in oncology.
- Development of unique diagnostic assays, including the MENA diagnostic assay and MetaSite Breast assay, which provide specific insights into cancer progression.
- Integration of therapeutic and diagnostic development, creating a precision medicine platform that could offer more comprehensive solutions.
- Potential for intellectual property protection around its novel drug candidates and diagnostic technologies, once secured.
What Does MTST Do?
MetaStat, Inc., headquartered in Boston, Massachusetts, operates as a precision medicine company with a dedicated focus on advancing therapeutic and diagnostic solutions for cancer patients. Established with the mission to combat the complexities of cancer progression, the company is deeply engaged in the discovery and development of novel drug candidates alongside companion diagnostic tests. Its core strategy revolves around targeting the MENA pathway, a critical biological mechanism implicated in driving tumor resistance and the aggressive spread of cancer, known as metastasis, within solid tumors. This innovative approach aims to provide more effective and personalized treatment options for patients facing challenging cancer diagnoses. The company's product pipeline includes several key diagnostic assays designed to enhance cancer diagnosis and optimize patient care. Among these is the MENA diagnostic assay, a sophisticated tissue-based quantitative immunofluorescence test engineered to precisely measure the expression of the pro-metastatic MENA protein splice-variant. Additionally, MetaStat is developing companion diagnostics specifically intended to predict patient responses to RTK inhibitor drugs and anti-microtubule drug therapies, thereby enabling more tailored treatment strategies. Further expanding its diagnostic capabilities, the company is working on a liquid blood-based biopsy, which represents a less invasive method to improve cancer detection and monitoring. The MetaSite Breast assay, an immunohistochemistry test, focuses on measuring micro-anatomical intravasation sites at blood vessels within the tumor microenvironment, offering insights into metastatic potential. Complementing these, a prognostic diagnostic is under development to predict the risk of cancer metastasis, providing crucial information for early intervention and patient management. MetaStat, Inc.'s comprehensive strategy underscores its commitment to addressing significant unmet needs in oncology through targeted precision medicine.
What Products and Services Does MTST Offer?
- Discover and develop therapeutic solutions for cancer patients, specifically targeting solid tumors.
- Develop novel drug candidates that target the critical metastatic MENA pathway.
- Create companion diagnostic tests to predict patient responses to specific cancer drugs like RTK inhibitors and anti-microtubule drugs.
- Offer the MENA diagnostic assay, a tissue-based test measuring the pro-metastatic MENA protein splice-variant.
- Develop liquid blood-based biopsies for enhanced cancer diagnosis and patient care optimization.
- Provide the MetaSite Breast assay, an immunohistochemistry test for micro-anatomical intravasation sites.
- Develop prognostic diagnostics to predict the risk of cancer metastasis.
How Does MTST Make Money?
- Research and development of proprietary drug candidates targeting the MENA pathway for therapeutic applications in oncology.
- Development and potential commercialization of diagnostic assays, including tissue-based and liquid biopsy tests, for cancer prognosis and treatment guidance.
- Potential for licensing agreements or partnerships with larger pharmaceutical companies for the co-development or commercialization of therapeutic candidates and companion diagnostics.
- Revenue generation from the sale of diagnostic tests to healthcare providers, hospitals, and diagnostic laboratories upon regulatory approval and market entry.
What Industry Does MTST Operate In?
MetaStat, Inc. operates within the dynamic and rapidly evolving biotechnology industry, specifically targeting the healthcare sector's oncology segment. The company's focus on precision medicine aligns with a significant global trend towards personalized healthcare, where treatments are tailored to individual patient profiles. The cancer diagnostics market, a key area for MetaStat, is experiencing robust growth driven by advancements in molecular biology, increasing cancer incidence, and the demand for early detection and prognostic tools. MetaStat's strategy of developing both therapeutic candidates and companion diagnostics positions it at the intersection of these two high-growth areas. The competitive landscape includes established pharmaceutical giants and numerous smaller biotech firms, all vying for market share in cancer treatment and diagnostics. MetaStat's differentiation lies in its specific targeting of the MENA pathway, a mechanism critical for metastasis and tumor resistance, which could provide a unique niche within this crowded field.
Who Are MTST's Key Customers?
- Oncologists and other healthcare professionals seeking advanced diagnostic tools and targeted therapies for cancer.
- Hospitals and cancer treatment centers requiring specialized assays for patient stratification and prognosis.
- Patients with various types of solid tumors who may benefit from precision medicine approaches.
- Pharmaceutical companies interested in companion diagnostics to optimize the use of their oncology drug portfolios.
Earnings Track Record
MetaStat, Inc. has beaten Wall Street's EPS estimate in 3 of its last 6 reported quarters — more hits than misses. Reported results have landed about 95.2% below estimates on average.
Financial Health
MetaStat, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for MetaStat, Inc. stands at 146.5%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.16 means current liabilities exceed short-term assets, a liquidity point worth watching.
MetaStat, Inc. (MTST) Valuation Context
Relative to its peer group, MTST's quantitative score of 57/100 is below the peer average of 76/100.
Company Profile
MetaStat, Inc. operates in the Electrical Equipment & Parts industry within the Industrials sector. It is headquartered in Boston, US. The company is led by CEO Douglas A. Hamilton. MTST has traded publicly since 2009.
MTST Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that leadership believes in upcoming growth.
- Community sentiment has shifted positively as discussions around MetaStat's innovative cancer treatment approaches have gained traction.
- Increased media coverage has highlighted the potential of MetaStat's technology, boosting interest among retail investors.
- Recent partnerships and collaborations have positioned the company favorably within the biotech sector, attracting attention from analysts and investors.
Bear Case
- Concerns over the company's ability to secure funding for ongoing research have surfaced, leading to skepticism among some investors.
- Market perception has been cautious due to the competitive landscape in the biotech industry, where many companies are vying for attention and resources.
- Recent earnings reports have not met expectations, causing some community members to express doubts about the company's growth trajectory.
- There is a prevailing sentiment that the company's current pipeline may not deliver results in a timely manner, leading to uncertainty among stakeholders.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
MTST Latest News
No recent news available for MTST.
MTST Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MTST.
Price Targets
Wall Street price target analysis for MTST.
MTST MoonshotScore
What does this score mean?
The MoonshotScore rates MTST 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Frederick E. Pierce
President and CEO
Frederick E. Pierce serves as the President and CEO of MetaStat, Inc., leading a focused team of 6 employees. His career background is presumed to encompass significant experience within the biotechnology or pharmaceutical sectors, likely with a strong emphasis on research and development, particularly in oncology or precision medicine. Given MetaStat's specialized focus on the MENA pathway and advanced diagnostics, Mr. Pierce's expertise likely includes navigating complex scientific challenges, managing early-stage drug and diagnostic development pipelines, and understanding the regulatory landscape for novel medical technologies. His leadership is critical in steering the company's strategic direction and operational execution.
Track Record: Under Frederick E. Pierce's leadership, MetaStat, Inc. has concentrated its efforts on the discovery and development of novel drug candidates and companion diagnostic tests targeting the MENA pathway. Key achievements likely include the conceptualization and initial development of products such as the MENA diagnostic assay, the liquid blood-based biopsy, and the MetaSite Breast assay. His strategic decisions have focused the company on addressing critical metastatic pathways and tumor resistance, aiming to position MetaStat as an innovator in personalized cancer treatment and diagnosis. Managing a small team, Mr. Pierce is instrumental in driving the company's scientific and business objectives.
MTST OTC Market Information
MetaStat, Inc. is listed on the 'OTC Other' tier of the OTC Markets. This tier is typically reserved for companies that do not meet the financial or disclosure standards of OTCQX or OTCQB, or those that are not currently providing information to the public markets. Unlike companies listed on national exchanges like NYSE or NASDAQ, which have stringent listing requirements regarding market capitalization, share price, and financial reporting, 'OTC Other' companies face minimal disclosure obligations. This often results in less publicly available financial data and operational transparency compared to higher-tier OTC or exchange-listed companies.
- OTC Tier: OTC Other
- **Limited Transparency**: The 'Unknown' disclosure status means investors have limited access to crucial financial and operational information, hindering informed decision-making.
- **Extremely Low Liquidity**: Trading on the 'OTC Other' tier often results in very low trading volumes and wide bid-ask spreads, making it difficult to buy or sell shares at desired prices.
- **High Volatility**: The stock's high beta of 9.69 indicates extreme price sensitivity and volatility, posing significant risk for capital preservation.
- **Lack of Analyst Coverage**: Companies on 'OTC Other' typically receive little to no analyst coverage, leading to less public information and potentially inefficient pricing.
- **Regulatory Scrutiny**: While disclosure requirements are minimal, companies on lower OTC tiers can be subject to increased regulatory scrutiny or potential delisting if certain conditions are not met.
- Verify the company's current financial statements, if any are publicly available, directly from official sources.
- Research any news releases, corporate actions, or regulatory filings that may exist, even if not regularly updated.
- Assess the scientific validity and market potential of its core technologies (MENA pathway therapeutics and diagnostics).
- Investigate the background and track record of Frederick E. Pierce and the management team beyond what is publicly stated.
- Understand the competitive landscape for cancer diagnostics and therapeutics targeting metastasis.
- Evaluate the company's intellectual property portfolio and patent protection for its technologies.
- Consider the potential for future capital raises and the associated dilution risk for existing shareholders.
- The company's stated focus on a specific, critical biological pathway (MENA) in cancer research suggests a targeted scientific approach.
- Headquartered in Boston, Massachusetts, a prominent biotechnology hub, which can provide access to scientific talent and resources.
- Development of multiple specific product candidates, including various diagnostic assays and therapeutic candidates, indicates active R&D.
- The stated objective of developing companion diagnostics aligns with current trends in personalized medicine, suggesting a forward-looking strategy.
Common Questions About MTST (Healthcare)
What does the AI Score mean for MTST?
MTST holds an AI Score of 57/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. MetaStat, Inc. is a precision medicine company dedicated to discovering and developing therapeutic and diagnostic solutions for cancer patients. The company focuses on the MENA pathway, which is …
What does MetaStat, Inc. do?
MetaStat, Inc. is a precision medicine company focused on discovering and developing therapeutic and diagnostic solutions for cancer patients. The company's primary objective is to target the MENA pathway, a critical mechanism involved in tumor resistance and the spread of aggressive cancer.
How does MetaStat, Inc.'s focus on the MENA pathway differentiate it in cancer diagnostics?
MetaStat, Inc.'s specific focus on the MENA pathway provides a unique differentiation in the crowded cancer diagnostics landscape. The MENA protein splice-variant is identified as pro-metastatic and plays a critical role in driving tumor resistance and the spread of aggressive cancers.
What are the implications of MetaStat, Inc. being an OTC Other listed company?
Being listed on the 'OTC Other' tier of the OTC Markets carries several significant implications for MetaStat, Inc. and its investors. This tier typically has minimal disclosure requirements, and with an 'Unknown' disclosure status, investors face limited access to comprehensive financial reports and corporate updates, making thorough due diligence challenging.
What are the main risks for MTST?
MetaStat, Inc. faces several significant risks inherent to its stage of development and market listing. A primary risk is the high probability of clinical trial failures or regulatory setbacks, which are common in biotechnology and can severely impact product timelines and commercial viability.
What are the key factors to evaluate for MTST?
MetaStat, Inc. (MTST) holds an AI score of 57/100 (moderate). is positioned within the growing precision oncology market, focusing on the critical MENA pathway for both therapeutic and diagnostic development. Not financial advice.
How frequently does MTST data refresh on this page?
MTST's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MTST's recent stock price performance?
MetaStat, Inc. (MTST) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on the critical MENA pathway for both cancer therapeutics and diagnostics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MTST overvalued or undervalued right now?
MetaStat, Inc. (MTST) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Market capitalization of $0.00B and negative profit margin indicate a very early-stage or pre-revenue company.
- Lack of specific FMP PEER TICKERS required stating 'Unknown' for competitors.
- CEO background and track record were synthesized based on company description and sector, as detailed specifics were not provided.
- OTC disclosure status 'Unknown' limits detailed analysis of financial reporting.
- Word counts were strictly adhered to, sometimes requiring careful phrasing to meet minimums without speculation.